Living Cell Technologies has received approval to go to the next phase of its New Zealand phase II human clinical trials for Diabecell, a newly formulated diabetes treatment.

The technology allowed doctors to place encapsulated insulin-producing cells in the abdomen of patients using a laparoscopic procedure.

The cells can self-regulate and secret the insulin required into the patient's body. The initial trial from eight patients showed positive results.

For the new trial which will commence on July, four patients shall be given higher doses.

Medicine